Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid

Valentina Bizzarro, Raffaella Belvedere, Maria Rita Milone, Biagio Pucci, Rita Lombardi, Francesca Bruzzese, Ada Popolo, Luca Parente, Alfredo Budillon, Antonello Petrella

Research output: Contribution to journalArticlepeer-review

Abstract

In this study, we have characterized the role of annexin A1 (ANXA1) in the acquisition and maintenance of stem-like/aggressive features in prostate cancer (PCa) cells comparing zoledronic acid (ZA)-resistant DU145R80 with their parental DU145 cells. ANXA1 is over-expressed in DU145R80 cells and its down-regulation abolishes their resistance to ZA. Moreover, ANXA1 induces DU145 and DU145R80 invasiveness acting through formyl peptide receptors (FPRs). Also, ANXA1 knockdown is able to inhibit epithelial to mesenchymal transition (EMT) and to reduce focal adhesion kinase (FAK) and metalloproteases (MMP)-2/9 expression in PCa cells. DU145R80 show a cancer stem cell (CSC)-like signature with a high expression of CSC markers including CD44, CD133, NANOG, Snail, Oct4 and ALDH7A1 and CSC-related genes as STAT3. Interestingly, ANXA1 knockdown induces these cells to revert from a putative prostate CSC to a more differentiated phenotype resembling DU145 PCa cell signature. Similar results are obtained concerning some drug resistance-related genes such as ATP Binding Cassette G2 (ABCG2) and Lung Resistant Protein (LRP). Our study provides new insights on the role of ANXA1 protein in PCa onset and progression.

Original languageEnglish
Pages (from-to)25076-25092
Number of pages17
JournalOncotarget
Volume6
Issue number28
DOIs
Publication statusPublished - 2015

Keywords

  • Annexin A1
  • Cancer stem cells
  • Cell invasion
  • EMT
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid'. Together they form a unique fingerprint.

Cite this